News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

Millions of people are living with Alzheimer's disease, a progressive, irreversible brain disorder that causes cognitive decline, confusion, memory loss, and many other symptoms. The Alzheimer's Assoc ...

Data from the Evoke trials suggests that GLP-1 drugs that treat type 2 diabetes do not have a significant effect on Alzheimer ...

The actor’s National Geographic documentary shows the power of memory and social connection in supporting his father’s ...

High levels of lead in blood are linked to increased risk for Alzheimer’s disease in older adults, but regular physical activity may reduce the risk, new research shows.

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Rutgers neuroscientist Peng Jiang and his neuroscience colleague Mengmeng Jin have made a discovery they say could reshape ...

Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer's disease that clears toxic amyloid ...